潘托拉唑治疗消化性溃疡并发出血的疗效观察

目的评价潘托拉唑（健朗晨）对消化性溃疡和所致上消化道出血的疗效和安全性，并与法莫替丁对比。方法选择胃十二指肠溃疡并发出血病人40例，潘托拉哇治疗组22例，其中胃溃疡（GU）10例，十二指肠球部溃疡（DU）12例。法莫替丁对照组18例，其中（GU）8例，（DU）10例。用药方法：潘托拉唑40mg口服，2次／d；法莫替丁20mg，2次／d，口服。结果治疗组48h内止血占27．3％，72h内止血占545％，无效率18．2％。对照组48h内止血11％，72h内止血占33％。无效率56％。两组总有效率有显著性差异，P〈0．05。结论潘托拉唑治疗消化性溃疡并发出血快速有效。3d内止血者占81．8％，无任何副作用，安全有效。     

静脉注射潘托拉唑与法莫替丁治疗消化性溃疡出血疗效观察

潘托拉唑是第三代质子泵抑制剂，对胃酸分泌具有强而持久的抑制作用，是治疗消化性溃疡的理想药物。我们200l～2003年50例消化性溃疡并出血病人分别用潘托拉唑和法莫替丁做对照，结果潘托拉唑对溃疡止血效果明显优于法莫替丁，现总结报道如下。     

泮托拉唑治疗消化性溃疡疗效观察

消化性溃疡(PU)是一种常见病，我们于2002-10／2003-10泮托拉唑治疗PU82例，获得满意结果，现报告如下。     

康复新液联合潘托拉唑治疗消化性溃疡疗效分析

目的研究康复新液与潘托拉唑联合治疗消化性溃疡（PU）的疗效。方法将经胃镜检查确诊的128例PU患者随机分为两组,治疗组65例,口服康复新液10ml每日3次,潘托拉唑40mg每日1次口服;对照组63例,口服潘托拉唑40mg每日1次。治疗期间每周1次随防,记录症状转归情况。疗程结束后,胃镜复查评估溃疡愈合情况。结果各项临床症状的改善和疼痛消失情况两组相比差异无显著性（P〉0.05）。PU的愈合率和总有效率治疗组为95.4%和98.5%。对照组为82.5%和87.3%,两组相比差异有显著性（P〈0.05）。两组在用药期间,不良反应少,均有良好的耐受性。结论康复新液联合潘托拉唑治疗PU可提高溃疡的愈合率和总有效率,缩短溃疡的愈合时间。     

潘托拉唑治疗消化性溃疡出血34例疗效观察

2004年6月-2006年6月,我们采用潘托拉唑治疗消化性溃疡出血34例,效果满意。现报告如下。 资料与方法：同期收治的消化性溃疡出血患者68例,男38例,女130例;年龄35—60岁,平均48岁。临床表现为柏油样便和（或）呕血,均经胃镜检查确诊为活动性消化性溃疡出血,其中胃溃疡（DU）17例,十二指肠溃疡（GU）51例,呕血5例;     

潘托拉唑钠注射液对消化性溃疡合并上消化道出血的疗效观察

上消化道出血临床颇为常见,往往起病急骤,病情危重。质子泵抑制剂的问世大大提高了消化性溃疡引起的上消化道出血的治愈率。注射用潘托拉唑钠系南京市海光应用化学研究所和扬州制药厂共同研制的新型质子泵抑制剂。２０００年４～１０月,上海市６所医院用该药治疗了６０例消化性溃疡伴出血患者,旨在验证该药对消化性溃疡引起的上消化道出血的疗效及安全性,现总结如下。 材料与方法 一、研究对象 ６０例消化性溃疡合并上消化道出血患者,男４２例,女１８例,年龄１８～７０岁,平均４７．２０岁±１５．２０岁。所有患者均因呕血、黑便…     

小剂量奥曲肽联合潘托拉唑治疗消化性溃疡大出血效果观察

将消化性溃疡大出血患者随机分成治疗组和对照组,分别应用小剂量和常规剂量奥曲肽联合潘托拉唑治疗.结果 两组有效率、再出血率、止血时问、出血情况比较均无统计学差异(P均＞0.05),均无明显不良反应.认为小剂量奥曲肽联合潘托拉唑方案高效、经济、安全可靠,可作为消化性溃疡大出血的首选治疗措施.     

Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer： A randomized, double-blind, controlled study

AIM： To evaluate the efficacy and tolerability of two different preparations of esomeprazole in healing duodenal ulcers. METHODS： A total of 60 patients with active duodenal ulcers were enrolled and randomized to receive esomeprazole enteric-coated capsules （40 mg） or esomeprazole magnesium （40 mg）, once daily, for 4 consecutive wk, with ulcer healing being monitored by endoscopy. Safety and tolerability were also assessed. RESULTS： Fifty seven patients completed the whole trial. The ulcer healing rates at the end of wk 2 were 86.7% and 85.2% in the esomeprazole enteric-coated capsules and esomeprazole magnesium groups, respectively （P = 0.8410）, and reached 100% at the end of wk 4 in beth groups. Symptom relief at the end of wk 2 was 90.8% in the esomeprazole enteric-coated capsules group and 86.7% in the esomeprazole magnesium group （P = 0.5406）; at the end of wk 4 symptom relief was 95.2% and 93.2%, respectively （P = 0.5786）. Adverse events occurred in 16.7% of the esomeprazole entericcoated capsules group and 14.8% of the esomeprazole magnesium group （P = 1.0000）. CONCLUSION： The efficacies of esomeprazole entericcoated capsules and esomeprazole magnesium in healing duodenal ulcer lesions and relieving gastrointestinal symptoms are equivalent. The tolerability and safety of beth drugs were comparable.     

雷贝拉唑钠治疗消化性溃疡的多中心临床研究

目的：评价雷贝拉唑钠10mg/d在消化性溃疡治疗中的疗效及安全性,并与奥美拉唑20mg/d进行比较。方法：采用随机开放对照临床研究,患者随机进入雷贝拉唑钠组（治疗组）或奥美拉唑组（对照组）,共有137例病人完成治疗,其中治疗组70例,对照组67例;治疗组口服雷贝拉唑钠片每次10mg,每日1次;对照组口服奥美拉唑胶囊每次20mg,每日1次。十二指肠球部溃疡疗程为4周,胃溃疡为6周。结果：两组治疗前后疼痛症状的改善及疼痛时间的消失,差异无显著性（P＞0．05）。十二指肠溃疡病人中,治疗组痊愈率和愈合率分别为38．5％和98．1％,对照组分别为26．0％和94．0％,两组间差异无显著性（P均＞0．05）。胃溃疡 病人中,治疗组痊愈率和愈合率分别为50．0％和100．0％,对照组分别为35．3％和94．1％,两组间差异无显著性（P均＞0．05）。整个试验过程中,治疗组和对照组不良反应率分别为4．3％和4．5％,两组间不良反应发生率相似（P＝1．000）。结论：雷贝拉唑钠10mg能安全、有效地治疗消化性溃疡,其缓解疼痛、促进溃疡愈合的疗效与奥美拉唑20mg相当。     

不同质子泵抑制剂对消化性溃疡出血的疗效及疗效-费用分析

目的对不同质子泵抑制剂对消化性溃疡出血的疗效及疗效-费用分析进行分析。方法83例消化性溃疡出血病人随机分为4组,分别给予:①静脉注射奥美拉唑40mg,q12h;②静脉注射奥美拉唑40mg,q12h,联合睡前一次静脉注射法莫替丁20mg;③静脉注射泮妥拉唑40mg,q12h;④静脉注射泮妥拉唑40mg,q12h,联合睡前一次静脉注射法莫替丁20mg。疗程均为5d。记录患者的止血时间、输血量、住院时间、转诊手术率、死亡率及住院总费用。结果4组患者的止血时间分别为1.3±1.0d、1.2±0.8d、1.3±0.8d、1.4±0.8d(P>0.05);输血量分别为1.7±2.8U、1.5±2.5U、1.6±2.4U、1.6±2.5U(P>0.05);再出血率为5.3%(1/19)、0、0、0(P>0.05);手术率和死亡率均为0;住院时间分别为10.6±7.4d、11.7±6.9d、12.9±5.9d、11.6±7.5d(P>0.05);住院总费用分别为7337.2±2133.1元、6908.6±2466.3元、7266.9±2993.1元、6646.3±2544.3元(P>0.05)。结论静脉注射奥美拉唑和泮妥拉唑均能有效治疗消化性溃疡出血,疗效及住院费用相当,夜间无需加用H2受体拮抗剂亦能达到同样疗效。     

奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的临床随机对照研究

目的　验证奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的生物等效性及评价其不良反应。方法　采用随机对照和开放试验的方法治疗经胃镜检查证实的消化性溃疡共 171例 ,其中奥美拉唑镁肠溶片组 (试验组 ) 68例 ,胃溃疡 2 1例 ,十二指肠溃疡 47例 ;奥美拉唑胶囊组 (对照组 ) 67例 ,其中胃溃疡 2 1例 ,十二指肠溃疡 46例 ;开放试验组 3 6例 ,其中十二指肠溃疡 2 9例 ,胃溃疡 7例。结果　试验组中胃溃疡的愈合率和总有效率分别为 80 9%和 10 0 %十二指肠溃疡的愈合率和总有效率分别为87 2 %和 97 8% ;对照组中胃溃疡的愈合率和总有效率为 85 7%和 95 2 % ,十二指肠溃疡的愈合率和总有效率为 84 7%和 97 8% ;开放试验组中胃溃疡的愈合率和总有效率均为 10 0 0 %十二指肠溃疡的愈合率和总有效率分别为 86 2 %和 10 0 % ;试验组中疼痛消失率及其他消化道症状的消失率在胃溃疡为 95 2 %和 89 0 %在十二指肠溃疡则为 97 8%和 98 3 % ;对照组中疼痛及其他消化道症状的消失率在胃溃疡为 95 2 %和 92 7% ,在十二指肠溃疡为 97 8%和 98 7%。两组在愈合率、总有效率、疼痛消失率和其他消化道症状消失率方面相比均无显著差别 (P >O 0 5 )。两组在治疗过程中均未见明显的不良反应。结论　奥美拉唑镁肠溶片与奥     

延边地区消化性溃疡4 348例胃镜分析

目的探讨少数民族地区消化性溃疡的发病学特点.方法分析1990年至1998年间延边地区的28547例内镜检查患者.结果在所有被检查患者中检出消化性溃疡4348例(15.23%),其中十二指肠溃疡2097例(48.22%),胃溃疡1921例(44.18%),复合性溃疡330例(7.59%).消化性溃疡中,男2974例(19.05%),女1374例(10.62%).男女检出率差异显著(P＜0.01);朝鲜族占2727例,汉族占1621例,检出率分别为13.96%和17.98%,但检出率差异显著(P＜0.01).结论延边地区消化性溃疡中汉族检出率高于朝鲜族,男性高于女性.     

泮托拉唑预防机械通气患者并发应激性溃疡的疗效研究

目的观察泮托拉唑在预防机械通气患者并发应激性溃疡中的临床疗效。方法 60例因严重肺部感染或慢性阻塞性肺病急性发作导致呼吸衰竭而行机械通气治疗的患者,随机分成两组,除基础治疗外,观察组(n=30)给予泮托拉唑40mg每日1次静脉滴注,对照组(n=30)不给予抑酸药物,观察两组患者上消化道出血的发生情况,并对发生上消化道出血患者行急诊胃镜检查,明确应激性溃疡诊断。同时记录两组患者的住院天数。结果观察组应激性溃疡的发生率(3.3%,1/30)明显低于对照组(20.0%,6/30)(P=0.044)。观察组平均住院时间(17.5±4.7)d也明显短于对照组(21.3±6.0)d(P=0.008)。结论泮托拉唑可有效预防因呼吸衰竭而接受机械通气治疗的患者中应激性溃疡的发生,并缩短住院时间。     

Efficacy of ilaprazole in the treatment of duodenal ulcers:A meta-analysis

AIM:To compare the efficacy and tolerance of ilaprazole compared with other proton pump inhibitors(PPIs)in the treatment of duodenal ulcer.METHODS:An electronic database search of Medline,Embase,the Cochrane controlled trials register,Web of Science,PubMed,and the Chinese Biomedical Literature Database(updated to July 2013),and manual searches were conducted.A meta-analysis of randomized controlled trials comparing the efficacy and tolerance of ilaprazole and other PPIs in the treatment of duodenal ulcers was performed.RESULTS:Five articles involving 1481 patients were included.The meta-analysis showed no difference in the4-wk healing rate between ilaprazole and other PPIs[89.7%vs 87.0%;relative risk(RR)=1.02;95%CI:0.98-1.06;Z=1.00;P=0.32].The results did not change in the sensitivity analyses.The meta-analysis indicated that the adverse effect rate in the ilaprazole group was lower than that in the control group,but the difference was not significant(9.7%vs 13.0%;RR=0.81;95%CI:0.60-1.07;Z=1.47;P=0.14).CONCLUSION:Ilaprazole is a highly effective and safe PPI in the treatment of duodenal ulcers.Ilaprazole can be recommended as a therapy for acid-related disorders,especially in Asian populations.     

Time, change and peptic ulcer disease in Rotherham, UK

BACKGROUND AND AIM: We have documented the changing pattern of peptic ulcer disease in our centre in the last quarter of the 20th century and speculate on the reasons thereof. PATIENTS AND METHODS: The profile of peptic ulcer disease patients presenting newly to our centre (population 250,000) from 1977 to 2001 was examined. All patients were prospectively followed and detailed records kept. Results are presented in 5-year periods. RESULTS: Seven thousand five hundred and ninety new peptic ulcer disease patients (5564 duodenal ulcer+2026 gastric ulcer) were seen, peaking in 1982-1986 but declining thereafter, and with a falling male preponderance. Patients with gastric ulcer were older than those with duodenal ulcer; were older than duodenal ulcer, the mean age of both increased over time and the age gap from the general population widened. The numbers presenting with perforation changed little but haemorrhage increased, particularly amongst the elderly. Ulcers refractory to H2 receptor antagonists declined even before proton pump inhibitors were introduced. Elective surgery, already declining before H2 receptor antagonists, had virtually disappeared by 1992-1996. DISCUSSION AND CONCLUSION: Peptic ulcer disease affects an older population, an increasing proportion of whom present with haemorrhage. Refractoriness to H2 receptor antagonists and the need for elective operation was declining even before the emergence of modern treatment. We suggest the changes observed result not only from modern therapy but also substantially from a changing natural history.     

奥美拉唑碳酸氢钠干混悬剂治疗消化性溃疡的多中心临床研究

目的:评价奥美拉唑碳酸氢钠干混悬剂治疗消化性溃疡的有效性和安全性。方法:本研究为多中心、随机、双盲、双模拟、阳性药物平行对照的Ⅱ期注册临床试验,根据适应证不同,分为十二指肠溃疡和胃溃疡2项研究,采用分层区组随机化方法将患者按1∶1随机分为试验组和对照组。试验组治疗方案为奥美拉唑碳酸氢钠干混悬剂[奥美拉唑20 mg(十二...     

Role of proton pump inhibitors in the management of peptic ulcer bleeding

Peptic ulcer bleeding is a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery and mortality in patients with bleeding peptic ulcers and is now recommended as the first hemostatic modality for these patients. The efficacy of large-dose proton pump inhibitor (PPI) therapy in reducing re-bleeding after endoscopic therapy has been supported by evidence derived from randomized controlled trials. It may be premature to recommend small-dose intravenous injection PPI after endoscopic hemostasis in patients with bleeding ulcers. An updated systematic review shows that PPI therapy before endoscopy significantly reduces the proportion with major stigmata and requirement for endoscopic therapy at index endoscopy. Some studies show that there is no significant difference between oral and intravenous PPIs in raising intragastric pH. However, clinical data is lacking in patients with peptic ulcer bleeding to date.